Sign in

CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
823562771
Phone
(650) 457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 36,342 shares at $1.34 ($48,698)
  2. 4 Open-market sale SVP, General Counsel sold 29,697 shares at $2.12 ($62,958)
  3. 4 Derivatives Options or other derivatives
  4. 4 Option exercise Director acquired 47,700 shares (option exercise)
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Open-market sale SVP, Finance sold 9,586 shares at $2.31 ($22,144)
  12. 4 Open-market sale SVP, Chief Technical Officer sold 2,867 shares at $2.50 ($7,168)
  13. 4 Open-market sale SVP, Chief Technical Officer sold 4,835 shares at $2.47 ($11,942)
  14. 4 Open-market sale President and CEO sold 47,763 shares at $2.47 ($117,975)
  15. 4 Open-market sale SVP, Chief Technical Officer sold 7,132 shares at $2.60 ($18,543)
  16. 4 Open-market sale SVP, Chief Technical Officer sold 7,549 shares at $1.73 ($13,060)
  17. 4 Open-market sale President and CEO sold 95,269 shares at $1.80 ($171,484)
  18. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 24,001 shares at $1.76 ($42,242)
  19. 4 Open-market sale SVP, General Counsel sold 22,900 shares at $1.76 ($40,304)
  20. 4 Open-market sale SVP, Finance sold 4,167 shares at $1.72 ($7,167)

Page 1 of 14 · 275 filings